AI
CV Therapeutics 3Q loss is narrower than expectations
November 06, 2007: 04:24 PM EST
NEW YORK, Nov. 6, 2007 (Thomson Financial delivered by Newstex) -- CV Therapeutics (NASDAQ:CVTX) Inc. reported a third-quarter net loss of $34.2 million, or 58 cents a share, narrower than the mean estimate of analysts surveyed by Thomson Financial of a loss of 62 cents a share.
Revenue rose to $19.8 million from $12.2 million in the same period a year ago, compared with analyst forecasts of $21.1 million.
Total costs and expenses for the quarter ending Sept. 30 fell to $53.7 million from last year's $76.3 million, and total cash utilized fell to $24.2 million from an adjusted $47.1 million a year ago.
The Palo Alto, Calif. biopharmaceutical company's stock closed Tuesday at $10.12.
no activity AH
November 06, 2007: 04:24 PM EST
NEW YORK, Nov. 6, 2007 (Thomson Financial delivered by Newstex) -- CV Therapeutics (NASDAQ:CVTX) Inc. reported a third-quarter net loss of $34.2 million, or 58 cents a share, narrower than the mean estimate of analysts surveyed by Thomson Financial of a loss of 62 cents a share.
Revenue rose to $19.8 million from $12.2 million in the same period a year ago, compared with analyst forecasts of $21.1 million.
Total costs and expenses for the quarter ending Sept. 30 fell to $53.7 million from last year's $76.3 million, and total cash utilized fell to $24.2 million from an adjusted $47.1 million a year ago.
The Palo Alto, Calif. biopharmaceutical company's stock closed Tuesday at $10.12.
no activity AH
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
